Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $4.7 million.

  • 4D Molecular Therapeutics' Depreciation & Amortization (CF) rose 5.97% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 1.82%. This contributed to the annual value of $4.7 million for FY2024, which is 10.68% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Depreciation & Amortization (CF) of $4.7 million as of FY2024, which was up 10.68% from $4.2 million recorded in FY2023.
  • 4D Molecular Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $4.7 million during FY2024, with a 5-year trough of $1.4 million in FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $4.2 million (2023), whereas its average is $3.8 million.
  • Data for 4D Molecular Therapeutics' Depreciation & Amortization (CF) shows a peak YoY spiked of 74.95% (in 2023) over the last 5 years.
  • 4D Molecular Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $1.4 million in 2020, then grew by 5.54% to $1.5 million in 2021, then skyrocketed by 57.78% to $2.4 million in 2022, then spiked by 74.95% to $4.2 million in 2023, then climbed by 10.68% to $4.7 million in 2024.